Effect of Recombinant Tuxtide Intervention on DSS-induced Acute UC Mouse Model.

Area of Science:

• Gastroenterology
• Molecular Biology
• Immunology

Background:

• Ulcerative colitis (UC) is a chronic inflammatory bowel disease with limited therapeutic options.
• Recombinant glucagon-like peptide-2 (GLP-2) and probiotics like Lactobacillus plantarum L9 are being explored for their therapeutic potential in inflammatory conditions.

Purpose of the Study:

• To investigate the therapeutic efficacy of recombinant GLP-2 (Tuxtide) and Lactobacillus plantarum L9, individually and in combination, for treating acute ulcerative colitis (UC).
• To provide insights for future therapeutic strategies for acute UC.

Main Methods:

• Bioinformatic prediction of a GLP-2 homologous peptide (Tuxtide) from Amphiuma tridactylum, followed by recombinant expression and purification.
• Establishment of an acute UC mouse model using 3% dextran sulfate sodium (DSS).
• Assessment of therapeutic effects through body weight, disease activity index, colon length, spleen index, histological scoring, and measurement of inflammatory markers (myeloperoxidase, IL-1β).

Main Results:

• Both Tuxtide and Lactobacillus plantarum L9 treatments improved colon length and body weight, and reduced disease activity index scores in DSS-induced UC mice compared to the control group.
• Tuxtide treatment showed the most significant improvement in body weight.
• Combination therapy (Tuxtide + L9) exhibited the strongest anti-inflammatory effects, significantly reducing colon histology scores and restoring intestinal crypts.

Conclusions:

• Recombinant GLP-2 (Tuxtide) and Lactobacillus plantarum L9 demonstrate significant therapeutic benefits in alleviating acute ulcerative colitis symptoms in a mouse model.
• The combination of Tuxtide and Lactobacillus plantarum L9 appears to be a promising therapeutic strategy for managing acute UC due to its enhanced anti-inflammatory properties.